Evidence map›Paper›PMID 33712704›Full record

ArticleOncogene2021

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.

Alfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, Mayra A Gonzalez, Rebecca Ellwood, Carme Ripoll Fiol, Christopher A Eide, Joshua J Lara, Christian Barreto-Vargas, Luis F Jave-Suarez and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Genetic mutation and immune infiltration in embryonal tumor with multilayered rosettes.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Alfonso E Bencomo-AlvarezCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Andres J RubioCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Idaly M OlivasGraduate School of Biomedical Sciences, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Mayra A GonzalezCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Rebecca EllwoodCentre for Haematology, Department of Medicine, Imperial College London, London, UK.
Carme Ripoll FiolCentre for Haematology, Department of Medicine, Imperial College London, London, UK.
Christopher A EideKnight Cancer Institute, Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
Joshua J LaraCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Christian Barreto-VargasUniversidad de Guadalajara, Guadalajara, Jalisco, México.
Luis F Jave-SuarezInstituto Mexicano del Seguro Social, Centro de Investigaciόn Biomédica de Occidente, Guadalajara, Jalisco, México.
Georgios NteliopoulosCentre for Haematology, Department of Medicine, Imperial College London, London, UK.
Alistair G ReidMolecular Pathology Unit, Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Liverpool, UK.
Dragana MilojkovicCentre for Haematology, Department of Medicine, Imperial College London, London, UK.
Brian J DrukerKnight Cancer Institute, Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-8331-8206
Jane ApperleyCentre for Haematology, Department of Medicine, Imperial College London, London, UK.
Jamshid S KhorashadCentre for Haematology, Department of Medicine, Imperial College London, London, UK.
Anna M EiringCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA. anna.eiring@ttuhsc.edu.ORCID http://orcid.org/0000-0001-6533-9150
Imperial College London · GBTexas Tech University · USOregon Health & Science University · USMexican Social Security Institute · MXUniversidad de Guadalajara · MXUniversity of Liverpool · GB

Funding

CHRONIC MYELOGENOUS LEUKEMIA AND BCR-ABL SUBSTRATESR01CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 1995 to 2021
$4.7M
G0S2 in Chronic Myeloid Leukemia Disease Progression and Imatinib ResistanceK22CA216008 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI EIRING, ANNA MARIE · 2018 to 2021
$704k
NCI NIH HHS K22 CA216008NCI NIH HHS R01 CA065823
6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have revolutionized therapy for chronic myeloid leukemia (CML), paving the way for clinical development in other diseases. Despite success, targeting leukemic stem cells and overcoming drug resistance remain challenges for curative cancer therapy. To identify drivers of kinase-independent TKI resistance in CML, we performed genome-wide expression analyses on TKI-resistant versus sensitive CML cell lines, revealing a nuclear factor-kappa B (NF-κB) expression signature. Nucleocytoplasmic fractionation and luciferase reporter assays confirmed increased NF-κB activity in the nucleus of TKI-resistant versus sensitive CML cell lines and CD34

Indexed as

AnimalsApoptosisDrug Resistance, NeoplasmHeterograftsHumansK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceMice, NudeNF-kappa BProteasome Endopeptidase ComplexProtein Kinase InhibitorsTranscription, GeneticUp-RegulationNF-kappa Bproteasome activator PA700 subunit p58, humanProteasome Endopeptidase ComplexProtein Kinase InhibitorsPSMD1 protein, human

Identifiers

PMID33712704
PMCPMC7952820
OpenAlexW3134887023

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.